For many years, chemo- and radiation therapies were the standard cancer treatments. However, these treatments are unspecific, cause severe side effects and often reduce the patients´ quality of life, with severely limited survival.
NOVEL CLASS OF HISTONE METHYLTRANSFERASE
We breaking the barriers of traditional limitations in the treatment of prostate and colon cancer. Our focus is on a new classes of epigenetic drugs. These drugs possess unmet efficacy and precision to make the world a healthier place.
Cure for prostate cancer on the horizon
Prostate cancer is the second most common cancer. According to the American Cancer Association, 1 in every 8 men will be diagnosed with it in their lifetime.
B66, a new company in Germany and a spin-off from the University of Freiburg, Germany, has strong preclinical evidence that its research has made a significant breakthrough after 6 years of dedicated work. Professors Roland Schule, Manfred Jung and Dr. Eric Metzger have pioneered research into inhibitors of the histone methyltransferase KMT9 that controls the growth of castration and enzalutamide resistant prostate tumors. These small molecular inhibitors are superior to current state-of-the-art Gold Standard drugs in preclinical models. This new treatment has the prospect of increasing survival in the normally fatal outcome of castration-resistant prostate cancer and becoming the universal therapeutic agent. In addition, the research team’s work shows that their new therapeutic agent has potentials in other cancers including colorectal, breast, bladder and the biggest of all killers, lung cancer.